Decreased risk of nosocomial transmission of hepatitis B virus and hepatitis C virus among hemodialysis patients from southern Bulgaria

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Re-engagement of formerly incarcerated people living with HIV lost to care

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Metabolic co-morbidities among people living with HIV (PLWH) in an urban specialist HIV clinic in the United Kingdom

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Impact of CRISPR-Cas gene cassettes on the packaging efficiency and transduction titer of lentiviral vectors

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

High levels of HIV-1 recombinants circulating in Portugal

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

CRISPR-Cas therapy towards a cure for HIV/AIDS

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

We need to talk about ART: a survey of clinicians and people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Economic evaluation of post-exposure prophylaxis-in-pocket (PIP) compared to pre-exposure prophylaxis (PrEP) for individuals with a low frequency of high-risk HIV exposures: a matched control study

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

The influence of concurrent low-dose oral calcium carbonate supplementation on steady state pharmacokinetics of once daily oral raltegravir

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Perceived knowledge, attitudes, and practices of major non-communicable diseases and their risk factors among people living with HIV in Rwanda

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Whole genome sequencing approach to identify HIV-1 drug resistance in clinical samples

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Immune responses after mpox infection or vaccination in a cohort of HIV-PrEP users

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Extinction of all infectious HIV in cell culture by the CRISPR-cjCas9 system

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Clinical impact of APOBEC mutations and prevalence in HIV antiretroviral resistance reports

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Ten years of HIV admissions at a tertiary infectious diseases centre: increased mortality and length of stay

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Update on transmitted resistances in treatment-naive patients in Spain (2022)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Effect of HIV treatment milestones on the HIV care continuum and AIDS diagnoses in CoRIS (2005-2022).

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Cabotegravir/rilpivirine long-acting for HIV treatment in a real-life setting: data from an Italian monocentric cohort

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Prevalence and risk factors of sarcopenia among people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Quantification of HIV RNA in cerebrospinal fluid

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Altered gut microbiota composition in virologically suppressed HIV-infected individuals on antiretroviral therapy: implications for chronic inflammation and metabolic health

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

NeuMoDx HIV viral load failure in a large group of Mayotte patients: viral diversity is still a challenge

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Familiarity of primary care physicians and infectious diseases specialists with PrEP and their willingness to prescribe it in the MENA region

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Gut innate immunity dysregulation and T cells activation go in parallel during HIV immunopathogenesis

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

HIV-DNA minority mutations profile in long-term infected paediatric population

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Elimination of infectious HIV DNA by CRISPR–saCas9

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Provision of care among migrants and refugees in a tertiary care center in Romania

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Intersection of HIV, biological considerations and comorbidities in women living with HIV: impact of online independent medical education on physician knowledge and confidence

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

A retrospective review of equivocal HIV serology results at a London (UK) teaching hospital

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Endoscopic features of gastric cryptosporidiosis in patients with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

High level of archived and circulating HIV-1 drug resistance mutations in adolescents with suppressed and unsuppressed viral loads in Cameroon

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HIV-1 quant assay compared to the established alinity m HIV-1 assay for routine viral load measurement

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

HIV prevalence rates amongst migrant sex workers in Europe

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

A framework to evaluate the effectiveness of models of care for people with HIV (PWH)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Delayed HIV diagnoses in the West of Ireland

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Distribution and relevance of hepatitis B genotypes in the general population of Slovakia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The characteristic of maternal HBV quasispecies is related to occult HBV infection of infants born to highly viremic mothers

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Repressed expression of human endogenous retroviruses HERV-K (HML-2) and HERV-9 in chronic hepatitis C patients with endogenous activation of the interferon system in the liver

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

New molecular assay for the detection and quantification of hepatitis B virus load in EDTA-plasma

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Is HBV RNA a promising biomarker in chronic hepatitis B?

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

On the road to Hepatitis C elimination, the need for screening beyond risk factors

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis Delta virus variability in Italy

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Diagnostic performance of two chemiluminescence immunoassays for the detection and quantification of hepatitis B virus surface antigen (HBsAg): a comparative study

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Surveillance of the zoonotic rat hepatitis E virus in rodents in Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation of RT-qPCR for the diagnosis of active hepatitis D virus (HDV) through a single-step approach

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Detection and quantification of hepatitis delta virus RNA by three different assays

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

An innovative strategy to relink into care patients with active HCV infection.

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Outbreak of acute hepatitis HCV in HIV-infected individuals

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Limited uptake of hepatitis D virus testing in people living with hepatitis B virus infection in Australia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis B infection and immunity in Timor-Leste: a population-representative serological survey

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis C virus (HCV) screening in an emergency department (ED), an effective strategy to hepatitis C elimination

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Analytic validation of a lab-developed qPCR assay for fully-automated high-throughput detection of Rocahepevirus ratti (ratHEV)

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Predictive factors for progression of fibrosis in chronic HBV infection on the indeterminate phase

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HBV Quant Assay compared to the established Alinity m HBV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HCV Quant Assay compared to the established Alinity m HCV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia: updated data

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Performance of a new fully automated platform for HIV, HBV and HCV viral load assessment

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation and usefulness of rapid molecular assay for hepatitis C virus RNA detection

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

A large outbreak of hepatitis A in a northern community in Canada 2021-2022: public health interventions and immunisation in a remote context

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation of the virological profile of pregnant women infected with the hepatitis B virus treated at a referral center in Rio de Janeiro, Brazil

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis E virus molecular surveillance in Hungary between 2018-2023 reveals infections with rare subtypes

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Profile of patients diagnosed with active HCV infection in an emergency department in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Opportunistic rescue of patients with HCV infection and lost in the healthcare system: results of the relink-C study in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

3Hdtect-Q real-time PCR kit for simultaneous detection and differentiation of HIV, HCV and HBV in human plasma, serum and whole blood samples

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Is it cost-effective to implement double reflex testing strategy to diagnose hepatitis D-superinfection? Reflections from Sweden representing a country with low prevalence of hepatitis B and D viruses

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Underdiagnosis of viral aetiologies in moderate-to-severe community-acquired pneumonia: an important clinical gap

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Phylogenetic lineage dynamics of global parainfluenza virus type 3 post-COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Nanobody-based PROTAC strategy provides broad-spectrum antiviral activity against porcine arterivirus

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Frequency of respiratory virus detection in the upper respiratory tract of hospitalised patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Beyond influenza and SARS-CoV-2: advancing respiratory sentinel surveillance in Sweden

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Prophylactic efficacy of CD388, a novel drug-Fc conjugate (DFC), in an influenza A/H3N2 human challenge model

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Influenza virus, SARS-CoV-2, respiratory syncytial virus, rhinovirus, adenovirus, bocavirus, and other respiratory virus circulation during 2022–2023 season in Latvia: focus on codetections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

The resurgence of influenza activity and out-of-season epidemics of RSV during the Omicron waves in Beijing, China

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Determination of RSV reinfection in a German population cohort between 2020 and 2023 using a newly established RSV antigen-derived 9-plex immunoassay (RSV MIA)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Risk of cardiovascular events after influenza: a population-based self-controlled case series study, Spain 2011-2018

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Evaluation and comparison of three case definitions for influenza detection in the same setting and population in the Valencia region of Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Rapid intra-season waning of vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Consumer preferences for features of influenza vaccines in the United Kingdom: results from a discrete-choice experiment study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

General population and healthcare professionals' level of knowledge of the burden and prevention of respiratory syncytial virus and other respiratory infections in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

A generic, saliva-based PCR test for the detection of RSV offers a low-burden approach for sustainable surveillance of RSV

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

A nationwide retrospective cohort study to assess the relative vaccine effectiveness of high-dose compared to standard dose influenza vaccines in France during the 2021-2022 season: results of a complementary analysis of DRIVEN study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Comparison of efficacy and safety between baloxavir marboxil and oseltamivir in outpatients with uncomplicated influenza: a real-world study of more than 1,500 patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Clinical characteristics, complications, and predictors of serious outcomes among adult outpatients with respiratory syncytial virus infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Clinical assessment of a fully automated RT-PCR assay for the qualitative detection of parainfluenza virus 1,3 and 2/4 in human nasal/throat swabs under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Evaluation of the clinical performance of a fully automated RT-PCR assay for the qualitative detection of RSV and hMPV in human nasal/throat swabs and bronchoalveolar lavage under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Higher waist circumference was associated with reduced cellular immune response to influenza vaccine: findings from the DYNAMIC cohort study of older adults in Singapore

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Relative effectiveness of an adjuvanted influenza vaccine vs non-adjuvanted influenza vaccines in high-risk older adults during the 2019-2020 U.S. influenza season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Cost-effectiveness of protective equipment stockpiles for reducing essential worker absenteeism in a pandemic: a modelling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Increased 90 days mortality associated with RSV compared to influenza among adults in Denmark

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Galectin-3 regulates viral pathogenesis and inflammation in H5N1 and H7N9 avian influenza virus infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Quantitative analysis of FluNet surveillance data: has B Yamagata really gone extinct?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Comparison of three commercial nucleic amplification tests for influenza A testing in a symptomatic patient population

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

RSV circulation in the SARS-Cov-2 pandemic era in the north of Spain (Asturias)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Influenza A and B viral loads are higher in nasopharyngeal swabs compared to mid-turbinate swabs

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Respiratory syncytial virus as single detection is associated with younger age and worse clinical outcomes

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Next-generation mRNA-based seasonal influenza vaccines including additional A/H3N2 strains: Phase 1/2 trial findings in adults aged 50-75 years

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Respiratory syncytial virus incidence trends during omicron COVID pandemic in older adults: a community-based prospective study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

The utility of multiplex real-time PCR screening for viral respiratory infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

A comparative study of the incidence, risk factors and outcome of hospitalised adults with RSV vs influenza A infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Tracking seasonal influenza trends in South Tyrol during season 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Enterovirus landscape in Barcelona: A virological surveillance journey through the 2020-2023 seasons in the shadow of the COVID-19 pandemics

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Seasonal trends in sentinel surveillance: a seven-year retrospective analysis from the Aegean region, Turkiye (2016-2023)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Unraveling the genetic, antigenic, and antiviral landscape of influenza viruses circulating in Catalonia (Spain) during the 2022-2023 season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Identification of granzymes as crucial regulators and potential targets of influenza-associated immunopathology and superinfections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Severe manifestations of parainfluenza type 4 infections in children

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Decoding severity: the GIHSN SevScale for hospitalised ARI cases

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Assessing the cost-effectiveness and public health impact of the adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in Canadian older adults

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Do pregnant women get the flu shot? A view over Greece

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Mapping the trends of non-SARS-CoV-2 respiratory viruses: a 2016–2023 analysis in a Rome hospital microbiology laboratory

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Digitally facilitated access to information on influenza complications and its prevention: a multicentric study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Estimation of RSV-attributable mortality in adults in Italy between 2015 and 2019

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Modelling the health and economics benefits of a rapid vaccine intervention in an influenza pandemic in the United Kingdom

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Changes in influenzavirus-A/B and human respiratory syncytial virus seasonality and activity during the COVID-19 pandemic in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Estimated impact of delayed influenza vaccine strain selection on vaccine effectiveness: a descriptive and modeling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Nosocomial acquisition, a zoom on respiratory viruses (NAZARE): A laboratory-based surveillance study to explore epidemiology and risk factors

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Impact of community pharmacy vaccination services on vaccination coverage of immunocompromised patients against respiratory tract infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Molecular epidemiology of rhinovirus: genotypes detected during and after the COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Setting the bar for new generation influenza vaccine reactogenicity: expected clinical and cost tradeoffs compared to standard-of-care vaccines

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Validation of a genome sequencing protocol for influenza B viruses

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Diversification of the ON1 genotype of HVRS-A on the coast of Peru during 2009-2020

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

The clinical and economic value of MF59-adjuvanted quadrivalent influenza vaccination in the elderly in Argentina

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Hospital and community epidemiology of SARS-CoV-2, influenza and RSV during 2022/2023 season in Auvergne-Rhône-Alpes, France: a comparative analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Economic burden of respiratory syncytial virus (RSV) and unspecified lower respiratory tract infection (UBP) during RSV season in adults in Germany (2015-2018): a health claims analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Subtyping and whole-genome sequencing of influenza A/B viruses using pan-subtype primers, widely-used library prep reagents, and cloud-based data analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Impact of COVID-19 pandemic on influenza vaccination rates among healthcare personnel at a tertiary-care centre in Lebanon

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Molecular investigation of seasonal viral respiratory outbreaks

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Respiratory syncytial virus burden in older adults (≥ 60 years): a two-year Italian multicentre study in the late COVID-19 pandemic and early post-pandemic period

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Serological investigation of RSV antibody responses in UK healthcare workers (SIREN study)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Self-collected saliva demonstrates utility for influenza surveillance by extraction-free PCR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Overview of adenovirus respiratory infections: preliminary findings of a multicentre study in Italy, 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Modelling the impact on carbon emissions of using a high dose influenza vaccine instead of standard dose among 65 years and older adults in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Comparison of burden of respiratory syncytial virus hospitalisation in paediatric population during two consecutive seasons 2021-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Early assessment of viral respiratory epidemics for the 2023/2024 season based on community laboratory surveillance network in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

A novel multiplex, quantitative immunoassay for anti-influenza IgG demonstrates individual variability in binding specificity targeting antigenically distinct haemagglutinin proteins

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Influenza like-illness surveillance using a Belgian sentinel network of nursing homes: results of October 2022 onwards

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Understanding antibody cross-reactivity between seasonal Influenza and H5N1 as a method to conduct H5N1-specific serosurveillance

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Serological responses to a boosted tetravalent influenza vaccine regimen in multiple myeloma patients: evaluating the impact of daratumumab treatment.

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Changing pattern of respiratory virus detection among severe acute respiratory syndrome corona virus: two symptomatic patients in the central province of Sri Lanka

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Investigating innovative system methods for the diagnosis of respiratory viruses for rapid clinical diagnosis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Impact of hospitalisations due to respiratory syncytial virus in a highly complex public paediatric hospital in Brazil, between January 2021 and May 2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Tasmania's COVID mitigation strategies provide insights into respiratory syncytial virus evolution

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Trends and severity of parainfluenza virus infections over the past decade

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Further characterisation of vaccine efficacy in infants from a Phase 3 RCT of a bivalent prefusion F RSV vaccine administered during pregnancy

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Impacts on respiratory viruses among hospitalised children with respiratory diseases after lifting COVID-19 restrictions

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Pre-immunisation landscape of human respiratory syncytial virus: genomic insights from Catalonia's SIVIC programme in the era of neutralising monoclonal antibody deployment

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Neutralising monoclonal antibodies raised against highly conserved influenza hemagglutinin, neuraminidase, and matrix epitopes may offer novel cocktail therapeutic strategies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Oxford Nanopore Sequencing revolutionizes Influenza surveillance in resource-limited settings

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Impact of influenza-related hospitalisation in Spain: characteristics and risk factor of mortality during five influenza seasons (2016 to 2021)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

CD388, a drug-Fc conjugate, shows long half-life in early clinical studies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Using nanopore amplicon sequencing data for rapid analysis of influenza type A

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Verification of the Savanna respiratory viral panel-4 as a rapid screening tool for respiratory viral infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

What was the burden of winter pressures on the UK SIREN healthcare worker cohort winter 2022-23?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Forecasting the epidemiological trends of pediatric acute respiratory infections at the community level using time series predictive models: an Italian scenario

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Evaluation of the performance of the Hologic Panther fusion 4 plex-assay

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

RSV viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Differences in influenza vaccination among healthcare workers: impact of work task, area of membership and gender

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 

Age-sex patterns of human herpesvirus infection seroprevalences among hospitalised patients in Paris area, France, 2016 to 2022

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cytomegalovirus reactivation in critically ill mechanically ventilated patients

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Validation of a herpes zoster conceptual model on quality of life in East Asia

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Clinical relevance of human herpesvirus-7 DNA detection in a tertiary care setting over a 13-year period

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Varicella-zoster virus circulating clades in a French tertiary referral centre, Paris, France, 2018-2023

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Oedema volume on admission may predict poor outcome in HSV-encephalitis, varies in reliability across aetiologies and lower oedema volumes

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Potential relationship between cytomegalovirus and immunosenescence: evidence from observational studies

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Incidence and risk factors for varicella-zoster virus central nervous system infections

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

The association between acyclovir-related neurotoxicity and its concentration

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Ganciclovir/valganciclovir therapy in congenital CMV infection: 24-year experience of a tertiary care children hospital in northern Italy

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

CMV plasma reactivation predicts CMV organ disease in patients with moderate to severe ulcerative colitis needing hospitalisation

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Immune response to human herpes virus in SARS-CoV-2 mild infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Review of laboratory testing and processing protocols for varicella zoster virus in a north London hospital

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Trends in hospitalisations related to herpes zoster in Denmark from 1998 to 2021

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

CMV infection in pregnancy: a 5-years clinical experience of the regional reference center for infections in pregnancy in a low-birth Italian region

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Management of CMV primary infection in pregnancy and neonatal outcome in the era of valacyclovir treatment: a monocentric prospective study

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Comparison of two IVDR molecular diagnostic assays for the detection of HSV-1, HSV-2 and VZV in lesions and ulcers.

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cytomegalovirus infection in patients hospitalised in intensive care

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Herpetic gingivostomatitis caused by human herpesvirus type 7: a new entity?

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

The role of Epstein-Barr virus in children with post-acute sequelae of SARS-CoV-2 infection in Taiwan

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Development and clinical validation of extraction-free loop-mediated isothermal amplification assays for rapid detection and subtyping of herpes simplex virus

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Antigen-specific immunoassays improve the serological staging of cytomegalovirus infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

sST2 is a potential biomarker for early prognostication of severe dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Steroid pulse therapy for severe fever with thrombocytopenia syndrome patients may not improve prognosis: retrospective analysis with overlap weighting using a national inpatient database

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development of a clinical scoring system to make a presumptive diagnosis of Kyasanur Forest disease: a case-control study from South India

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Autochtonous dengue outbreak in Lombardy region, Italy, 2023: results of a seroprevalence study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Effect of montelukast in preventing dengue with warning signs among patients with dengue: a multicentre, randomised, double-blind, placebo-controlled trial

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Exploratory analysis of the knowledge, attitudes and perceptions of healthcare workers about arboviruses in the context of surveillance in the Republic of Guinea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

NS1-based IgG FcγR Enzyme-Linked Immunosorbent Assays allow serological differential diagnosis of dengue and zika virus infections in both returning travellers and individuals from endemic regions

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

NanoHarmony: unleashing silver's whisper in swift Zika detection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Factors associated with mpox vaccination willingness and uptake among men who have sex with men

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Intensified surveillance for tick-borne encephalitis to identify possible places of infection in Bavaria, Germany, May–October 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Lassa virus: unravelling the within-host evolutionary dynamics of acute and persistent infections and the virulence evolution among hosts

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Correlation between the cycle threshold values of medium- and small-segment severe fever with thrombocytopenia syndrome virus and viral load: prognostic implications

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Do infectious diseases specialists and neurologists manage patients with tick-borne encephalitis differently?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A ‘living' rapid research needs appraisal platform for WHO priority diseases: henipavirus evidence-gaps

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Laboratory results of mpox suspected cases tested by differential diagnostic panel during the mpox outbreak in Hungary in 2022/2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Exploring mpox genome variations amidst the 2022 outbreak

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

First detection of the zoonotic rat hepatitis E virus in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical importance of Alongshan virus, a new tick-borne Flaviviridae virus: a retrospective serological and molecular study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Assessing the synergistic insecticidal activity of Syzygium aromaticum and Citrus aurantifolia leaf extract combination against Aedes vectors

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Orthopoxvirus differential diagnosis by neutralising antibodies in mpox patients and vaccinated individuals

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

MCP-3 as a prognostic biomarker for severe fever with thrombocytopenia syndrome: a longitudinal cytokine profile Study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Prospective evaluation of serum cytokines and musculoskeletal ultrasound as surrogate markers for chronic post-chikungunya rheumatism

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A question from an endemic area: which diseases are included in the differential diagnosis with CCHF?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Increased likelihood of leukopenia, thrombocytopenia, and other characteristics in Crimean-Congo haemorrhagic fever patients: a systematic review and analysis of clinical factors that indicate infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dengue vaccine: a risk model to prioritise and maximize the impact of a dengue vaccination program in Peru

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mayaro virus and chikungunya virus IgM and IgG testing in parallel improves diagnosis of acute mayaro virus infections

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Epidemiology trends of infections and outbreaks of Crimean-Congo hemorrhagic fever worldwide, 2017-2023.

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Strengthening preparedness to arbovirus infections in Europe: a prospective, observational study in southeast Europe

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Expression of galectin-3 ameliorates zika virus infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Assessing the endemicity of Japanese encephalitis in central India: a comprehensive study of human and animals in Madhya Pradesh

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A meta-analysis and mapping of global mpox infection among children and adolescents

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical presentation and viral shedding in patients with mpox in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical-laboratory features and predictive factors for sequelae of tick-borne encephalitis virus infection: a retrospective observational study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Tick of the iceberg: using a One Health approach to assess and respond to the threat of tick-borne encephalitis in England

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Relation of WNV seroprevalence with ABO and D blood groups among blood donors: implication for transfusion safety

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical and microbiological study of bacterial or fungal co-infections in severe fever with thrombocytopenia syndrome

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Enhancing clinical diagnosis of dengue: performance evaluation of NS1 antigen and IgG/IgM antibody tests

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mpox in Colombia: an analysis of the 4,114 PCR confirmed cases in June 2022-November 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Co-detection of RNA and DNA viruses in a single library prep and enrichment workflow

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Results from a large-scale dengue diagnostic accuracy systematic review and meta-analysis: NS1 ELISA performs similarly to RT-PCR

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

TBE vaccination: insights from a KAB survey among Lyme borreliosis cases in Bavaria, Germany, 2019

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Children hospitalised with Crimean-Congo haemorrhagic fever in Turkiye have different clinical and diagnostic features and lower mortality than adults, implying that diagnostic criteria and illness severity scoring systems need adaptation for use in children

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Elevated plasma level of IP-10 /CXCL10 is correlated with severity of human West Nile virus (WNV) infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Effect of severe fever with thrombocytopenia syndrome virus genotype on disease severity, viral load, and cytokines in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical findings and IL-6 levels in patients with dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Arthropod-borned zoonosis in Cádiz, south of Spain: serological prevalence in a high-risk group

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development and validation of the PLNA score to predict cytokine storm in patients with acute phase of SFTS: a single-center cohort study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Hybrid capture-based next-generation sequencing: implementation for Lassa virus for the recovery of in-depth viral genomic data

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development of a multiplexed serological mpox assay for diagnostics, serosurveillance, and immunology studies

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Genotypic diversity and molecular characterisation of DENV-2 in endemic areas of Peru during 2016-2021

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

The clinical characteristics of human mpox disease before and after the 2022 outbreak: any difference? a metaanalysis study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Early identification of complex biomarker signatures predicting plasma leakage in dengue patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Genetic characteristics of aigai virus: a recently reclassified orthonairovirus

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Knowledge, risk perception and attitudes about mpox and the implementation of preventive measures in people belonging to the LGTBIQ+ community in Colombia

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Adjuvanted unconjugated highly conserved multi-epitope influenza peptide vaccine induced broadly reactive antibodies to multiple influenza viruses in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Investigating the pathogenesis of Middle East respiratory syndrome coronavirus infection using a quantitative phosphoproteomics approach

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Evaluation of viral load and neutralising antibody levels in Crimean-Congo hemorrhagic fever patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nanopore sequencing of RdRp gene used as a genetic marker for characterization of coronaviruses in clinical samples

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mpox experience at a tertiary infectious diseases centre in a tropical country between 2022-2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Combining phylogeographic and niche modelling approaches to investigate the ecological drivers of TBEV at the Palearctic scale

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Chikungunya in Colombia, 2022: An analysis of the cases notified to the National Surveillance System in the midst of South American reemergence

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dengue epidemics in Colombia, 2023: an analysis of the cases notified to the national surveillance system

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Minor clinical sequelae and absence of viral persistence: an 8-month follow-up study of former mpox patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Sero-catalytic and spatial modeling of dengue force-of-infection from age-stratified seroprevalence data in Timor-Leste

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)